Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics

Biomolecules and Therapeutics

Volumn 23, Issue 6, 2015, Pages 493-509

  Kim, Eunhee G ^a   Kim, Kristine M ^a,b  

^a Department of Systems Immunology   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

Antibodies; Antibody drug conjugates; Immunotherapy; Targeted therapy

Indexed keywords

AMANITIN; ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; DOXORUBICIN; DUOCARMYCIN DERIVATIVE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INOTUZUMAB OZOGAMICIN; MAYTANSINE; MDX 1203; MONOCLONAL ANTIBODY; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; BINDING AFFINITY; CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROCESS OPTIMIZATION; REVIEW; STOICHIOMETRY;

EID: 84944725121     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2015.116     Document Type: Review

References (102)

1. Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I. G., Schuler, M., Sierra, J., Smith, M. R., Verhoef, G., Winter, J. N., Boni, J., Vandendries, E., Shapiro, M. and Fayad, L. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J. Clin. Oncol. 28, 2085-2093.
2. Albin, N., Massaad, L., Toussaint, C., Mathieu, M. C., Morizet, J., Parise, O., Gouyette, A. and Chabot, G. G. (1993) Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res. 53, 3541-3546.
3. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J. and Senter, P. D. (2008) Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates. Bioconjug. Chem. 19, 759-765.
4. Ansell, S. M., Horwitz, S. M., Engert, A., Khan, K. D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., Fischkoff, S., Assad, A. and Borchmann, P. (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol. 25, 2764-2769.
5. Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., Lu, Y., Tran, H., Seller, A. J., Biroc, S. L., Szydlik, A., Pinkstaff, J. K., Tian, F., Sinha, S. C., Felding-Habermann, B., Smider, V. V. and Schultz, P. G. (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad Sci. U.S. A. 109, 16101-16106.
6. Bai, R. L., Pettit, G. R. and Hamel, E. (1990) Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10. Biochem. Pharmacol. 40, 1859-1864.
7. Beck, A., Senter, P. and Chari, R. (2011) World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs 3, 331-337.
8. Boeggeman, E., Ramakrishnan, B., Kilgore, C., Khidekel, N., Hsieh-Wilson, L. C., Simpson, J. T. and Qasba, P. K. (2007) Direct identification of nonreducing GlcNAc residues on N-glycans of glycoproteins using a novel chemoenzymatic method. Bioconjug. Chem. 18, 806-814.
9. Boeggeman, E., Ramakrishnan, B., Pasek, M., Manzoni, M., Puri, A., Loomis, K. H., Waybright, T. J. and Qasba, P. K. (2009) Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug. Chem. 20, 1228-1236.
10. Boger, D. L. (1993) Design, synthesis, and evaluation of DNA minor groove binding agents. Pure Appl. Chem. 65, 1123-1132.
11. Boger, D. L. and Johnson, D. S. (1995) CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl. Acad Sci. U.S.A. 92, 3642-3649.
12. Bross, P. F., Beitz, J., Chen, G., Chen, X. H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. and Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer. Res. 7, 1490-1496.
13. Carrico, I. S., Carlson, B. L. and Bertozzi, C. R. (2007) Introducing genetically encoded aldehydes into proteins. Nat. Chem. Biol. 3, 321-322.
14. Cassady, J. M., Chan, K. K., Floss, H. G. and Leistner, E. (2004) Recent developments in the maytansinoid antitumor agents. Chem. Pharm. Bull. (Tokyo) 52, 1-26.
15. Chen, Y., Liu, G., Guo, L., Wang, H., Fu, Y. and Luo, Y. (2015) Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration. Int. J. Cancer 136, 182-194.
16. Corrie, P. G. (2008) Cytotoxic chemotherapy: clinical aspects. Medicine 36, 24-28.
17. De Groot, F. M., Beusker, P. H., Scheeren, J. W., De Vos, D., Van Berkom, L. W. A., Busscher, G. F., Seelen, A. E., RKoekkoek, R. and Albrecht, C. (2007). ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS. Patent U.S. 7223837 B2.
18. Deutsch, Y. E., Tadmor, T., Podack, E. R. and Rosenblatt, J. D. (2011) CD30: an important new target in hematologic malignancies. Leuk Lymphoma 52, 1641-1654.
19. Dijoseph, J. F., Dougher, M. M., Armellino, D. C., Evans, D. Y. and Damle, N. K. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21, 2240-2245.
20. Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A., Jack, A., Junutula, J. R., Koeppen, H., Lau, J., McBride, J., Rawstron, A., Shi, X., Yu, N., Yu, S. F., Yue, P., Zheng, B., Ebens, A. and Polson, A. G. (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114, 2721-2729.
21. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., Wahl, A. F. and Senter, P. D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17, 114-124.
22. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L. and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-784.
23. Eisenbeis, C. F., Caligiuri, M. A. and Byrd, J. C. (2003) Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clin. Cancer Res. 9, 5810-5812.
24. Elias, D. J., Kline, L. E., Robbins, B. A., Johnson, H. C., Jr., Pekny, K., Benz, M., Robb, J. A., Walker, L. E., Kosty, M. and Dillman, R. O. (1994) Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am. J. Respir. Crit. Care Med. 150, 1114-1122.
25. Ellestad, G. A. (2011) Structural and conformational features relevant to the anti-tumor activity of calicheamicin gamma 1I. Chirality 23, 660-671.
26. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S. and Blattler, W. A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426-4433.
27. Forero-Torres, A., Leonard, J. P., Younes, A., Rosenblatt, J. D., Brice, P., Bartlett, N. L., Bosly, A., Pinter-Brown, L., Kennedy, D., Sievers, E. L. and Gopal, A. K. (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br. J. Haematol. 146, 171-179.
28. Gajria, D. and Chandarlapaty, S. (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev. Anticancer Ther. 11, 263-275.
29. Gerber, H. P. (2010) Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem. Pharmacol. 79, 1544-1552.
30. Giles, F. J., Kantarjian, H. M., Kornblau, S. M., Thomas, D. A., Garcia-Manero, G., Waddelow, T. A., David, C. L., Phan, A. T., Colburn, D. E., Rashid, A. and Estey, E. H. (2001) Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92, 406-413.
31. Hallen, H. E., Luo, H., Scott-Craig, J. S. and Walton, J. D. (2007) Gene family encoding the major toxins of lethal Amanita mushrooms. Proc. Natl. Acad Sci. U.S.A. 104, 19097-19101.
32. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A. and Bernstein, I. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 13, 40-46.
33. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L. and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070.
34. Hofer, T., Skeffington, L. R., Chapman, C. M. and Rader, C. (2009) Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry 48, 12047-12057.
35. Hommelgaard, A. M., Lerdrup, M. and van Deurs, B. (2004) Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol. Biol. Cell 15, 1557-1567.
36. Horn-Lohrens, O., Tiemann, M., Lange, H., Kobarg, J., Hafner, M., Hansen, H., Sterry, W., Parwaresch, R. M. and Lemke, H. (1995) Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int. J. Cancer 60, 539-544.
37. Ingle, G. S., Chan, P., Elliott, J. M., Chang, W. S., Koeppen, H., Stephan, J. P. and Scales, S. J. (2008) High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br. J. Haematol. 140, 46-58.
38. Jain, N., O'Brien, S., Thomas, D. and Kantarjian, H. (2014) Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Front Biosci (Elite Ed) 6, 40-45.
39. Jeffrey, S. C., Andreyka, J. B., Bernhardt, S. X., Kissler, K. M., Kline, T., Lenox, J. S., Moser, R. F., Nguyen, M. T., Okeley, N. M., Stone, I. J., Zhang, X. and Senter, P. D. (2006) Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug. Chem. 17, 831-840.
40. Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L., Miyamoto, J. B. and Senter, P. D. (2007) Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker. Bioorg. Med. Chem. Lett. 17, 2278-2280.
41. Jeffrey, S. C., Torgov, M. Y., Andreyka, J. B., Boddington, L., Cerveny, C. G., Denny, W. A., Gordon, K. A., Gustin, D., Haugen, J., Kline, T., Nguyen, M. T. and Senter, P. D. (2005) Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J. Med. Chem. 48, 1344-1358.
42. Jeger, S., Zimmermann, K., Blanc, A., Grunberg, J., Honer, M., Hunziker, P., Struthers, H. and Schibli, R. (2010) Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. Engl. 49, 9995-9997.
43. Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H. and Lowman, H. B. (2008a) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332, 41-52.
44. Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., Mai, E., Lewis Phillips, G. D., Hiraragi, H., Fuji, R. N., Tibbitts, J., Vandlen, R., Spencer, S. D., Scheller, R. H., Polakis, P. and Sliwkowski, M. X. (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res. 16, 4769-4778.
45. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. D., Lee Wong, W., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P. and Mallet, W. (2008b) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925-932.
46. Kantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., Rios, M. B., Cortes, J., Fayad, L., Tarnai, R., Wang, S. A., Champlin, R., Advani, A. and O'Brien, S. (2012) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 13, 403-411.
47. Katz, J., Janik, J. E. and Younes, A. (2011) Brentuximab Vedotin (SGN-35) Clin. Cancer Res. 17, 6428-6436.
48. Kellogg, B. A., Garrett, L., Kovtun, Y., Lai, K. C., Leece, B., Miller, M., Payne, G., Steeves, R., Whiteman, K. R., Widdison, W., Xie, H., Singh, R., Chari, R. V. J., Lambert, J. M. and Lutz, R. J. (2011) Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug. Chem. 22, 717-727.
49. Kim, K. M., McDonagh, C. F., Westendorf, L., Brown, L. L., Sussman, D., Feist, T., Lyon, R., Alley, S. C., Okeley, N. M., Zhang, X., Thompson, M. C., Stone, I., Gerber, H. P. and Carter, P. J. (2008) Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol. Cancer Ther. 7, 2486-2497.
50. Kim, Y. S., Park, T., Woo, S., Lee, H., Kim, S., Kwon, H., Oh, K., Chung, Y. and Park, Y. H. (2014) ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE. US Patent Application 20140187756 A1.
51. Koblinski, J. E., Ahram, M. and Sloane, B. F. (2000) Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135.
52. Koppe, M. J., Postema, E. J., Aarts, F., Oyen, W. J., Bleichrodt, R. P. and Boerman, O. C. (2005) Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 24, 539-567.
53. Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., Zeng, W., Harrington, K. H., Klussman, K., Westendorf, L., Meyer, D., Bernstein, I. D., Senter, P. D., Benjamin, D. R., Drachman, J. G. and McEarchern, J. A. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122, 1455-1463.
54. Larson, R. A., Sievers, E. L., Stadtmauer, E. A., Lowenberg, B., Estey, E. H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J. M., Richie, M., Leopold, L. H., Berger, M. S., Sherman, M. L., Loken, M. R., van Dongen, J. J., Bernstein, I. D. and Appelbaum, F. R. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104, 1442-1452.
55. Lee, M. D., Dunne, T. S., Chang, C. C., Siegel, M. M., Morton, G. O., Ellestad, G. A., McGahren, W. J. and Borders, D. B. (1992) Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins.beta.1Br,.gamma.1Br,.alpha.2I,.alpha.3I,.beta.1I,.gamma.1I, and.delta.1I. J. Am. Chem. Soc. 114, 985-997.
56. Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Furman, R., Schuster, M. W., Feldman, E. J., Ashe, M., Schuster, S. J., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., Gayko, U., Fields, S. Z., Cesano, A. and Goldenberg, D. M. (2004) Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res. 10, 5327-5334.
57. Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., Wong, W. L. T., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D. and Sliwkowski, M. X. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290.
58. Lindell, T. J., Weinberg, F., Morris, P. W., Roeder, R. G. and Rutter, W. J. (1970) Specific inhibition of nuclear RNA polymerase II by alpha-amanitin. Science 170, 447-449.
59. Liu, W., Brock, A., Chen, S., Chen, S. and Schultz, P. G. (2007) Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat. Methods 4, 239-244.
60. Maloney, D. G., Liles, T. M., Czerwinski, D. K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. and Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457-2466.
61. Mason, S. D. and Joyce, J. A. (2011) Proteolytic networks in cancer. Trends Cell Biol. 21, 228-237.
62. McDonagh, C. F., Kim, K. M., Turcott, E., Brown, L. L., Westendorf, L., Feist, T., Sussman, D., Stone, I., Anderson, M., Miyamoto, J., Lyon, R., Alley, S. C., Gerber, H. P. and Carter, P. J. (2008) Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol. Cancer Ther. 7, 2913-2923.
63. McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A. and Carter, P. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Des. Sel. 19, 299-307.
64. Moldenhauer, G., Salnikov, A. V., Luttgau, S., Herr, I., Anderl, J. and Faulstich, H. (2012) Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J. Natl. Cancer Inst. 104, 622-634.
65. Moolten, F. L. and Cooperband, S. R. (1970) Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science 169, 68-70.
66. Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d'Amore, F., Gonzalez Diaz, M., Petrini, M., Sebban, C., Zinzani, P. L., van Oers, M. H., van Putten, W., Bischof-Delaloye, A., Rohatiner, A., Salles, G., Kuhlmann, J. and Hagenbeek, A. (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 26, 5156-5164.
67. Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., Osmanov, D., Bachanova, V., Sweetenham, J., Sureda, A., Huebner, D., Sievers, E. L., Chi, A., Larsen, E. K., Hunder, N. N., Walewski, J. and Group, A. S. (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385, 1853-1862.
68. Oflazoglu, E., Stone, I. J., Gordon, K., Wood, C. G., Repasky, E. A., Grewal, I. S., Law, C. L. and Gerber, H. P. (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin. Cancer Res. 14, 6171-6180.
69. Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D. and Alley, S. C. (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 16, 888-897.
70. Oroudjev, E., Lopus, M., Wilson, L., Audette, C., Provenzano, C., Erickson, H., Kovtun, Y., Chari, R. and Jordan, M. A. (2010) Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther. 9, 2700-2713.
71. Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G. and Neri, D. (2014) Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res. 74, 2569-2578.
72. Petersen, B. H., DeHerdt, S. V., Schneck, D. W. and Bumol, T. F. (1991) The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 51, 2286-2290.
73. Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., Frantz, G., Fuji, R. N., Gray, A., Harden, K., Ingle, G. S., Kljavin, N. M., Koeppen, H., Nelson, C., Prabhu, S., Raab, H., Ross, S., Slaga, D. S., Stephan, J. P., Scales, S. J., Spencer, S. D., Vandlen, R., Wranik, B., Yu, S. F., Zheng, B. and Ebens, A. (2009) Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 69, 2358-2364.
74. Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, D. A. and Shustov, A. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190-2196.
75. Rabuka, D., Rush, J. S., deHart, G. W., Wu, P. and Bertozzi, C. R. (2012) Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc. 7, 1052-1067.
76. Ramakrishnan, B. and Qasba, P. K. (2002) Structure-based design of beta 1,4-galactosyltransferase I (beta 4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens beta 4Gal-T1 donor specificity. J. Biol. Chem. 277, 20833-20839.
77. Ravry, M. J., Omura, G. A. and Birch, R. (1985) Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. Am. J. Clin. Oncol. 8, 148-150.
78. Remillard, S., Rebhun, L. I., Howie, G. A. and Kupchan, S. M. (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189, 1002-1005.
79. Ricart, A. D. (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 17, 6417-6427.
80. Saito, G., Swanson, J. A. and Lee, K. D. (2003) Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55, 199-215.
81. Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N. and LoBuglio, A. F. (2000) Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 18, 2282-2292.
82. Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M., Doronina, S. O., Siadak, A. W., Senter, P. D. and Wahl, A. F. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-852.
83. Sanofi (2014) Phase II two stage finding run in study of SAR3419, an anti-CD19 antibody-maytansine conjugate, administered as a single agent by intravenous infusion in patients with relapsed or refractory acute lymphoblastic leukemia- clinicaltrtals.gov NCT01440179 last updated august 26, 2014. .
84. Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S. V., Cardillo, T. M., Hansen, H. J., Horak, I. D., Griffiths, G. L. and Goldenberg, D. M. (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin. Cancer Res. 11, 5257-5264.
85. Scott, A. M., Lee, F. T., Tebbutt, N., Herbertson, R., Gill, S. S., Liu, Z., Skrinos, E., Murone, C., Saunder, T. H., Chappell, B., Papenfuss, A. T., Poon, A. M., Hopkins, W., Smyth, F. E., MacGregor, D., Cher, L. M., Jungbluth, A. A., Ritter, G., Brechbiel, M. W., Murphy, R., Burgess, A. W., Hoffman, E. W., Johns, T. G. and Old, L. J. (2007) A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl. Acad Sci. U.S.A. 104, 4071-4076.
86. Seattle Genetics (2015) Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse, Seattle Genetics company website. http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2017717, Feb. 18, 2015
87. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S. F., Mai, E., Li, D., Tibbitts, J., Baudys, J., Saad, O. M., Scales, S. J., McDonald, P. J., Hass, P. E., Eigenbrot, C., Nguyen, T., Solis, W. A., Fuji, R. N., Flagella, K. M., Patel, D., Spencer, S. D., Khawli, L. A., Ebens, A., Wong, W. L., Vandlen, R., Kaur, S., Sliwkowski, M. X., Scheller, R. H., Polakis, P. and Junutula, J. R. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30, 184-189.
88. Steiner, M. and Neri, D. (2011) Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin. Cancer Res. 17, 6406-6416.
89. Strop, P., Liu, S. H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T. T., Ho, W. H., Farias, S., Casas, M. G., Abdiche, Y., Zhou, D., Chandrasekaran, R., Samain, C., Loo, C., Rossi, A., Rickert, M., Krimm, S., Wong, T., Chin, S. M., Yu, J., Dilley, J., Chaparro-Riggers, J., Filzen, G. F., O'Donnell, C. J., Wang, F., Myers, J. S., Pons, J., Shelton, D. L. and Rajpal, A. (2013) Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20, 161-167.
90. Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., Jonak, Z. L., Johnson, R., DeWitte, M., Martino, H., Audette, C., Maes, K., Chari, R. V., Lambert, J. M. and Rowinsky, E. K. (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21, 211-222.
91. Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N. and Slichenmyer, W. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 17, 478-484.
92. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellstrom, I. and Hellstrom, K. E. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261, 212-215.
93. Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R. and Anderson, K. C. (1991) Tumor cell expression of CD59 Is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24, 263-271.
94. Ulbrich, K. and Subr, V. (2004) Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev. 56, 1023-1050.
95. van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martinez-Martinez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., De Baets, M. H., van de Winkel, J. G., Aalberse, R. C. and Parren, P. W. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554-1557.
96. van Der Velden, V. H., te Marvelde, J. G., Hoogeveen, P. G., Bernstein, I. D., Houtsmuller, A. B., Berger, M. S. and van Dongen, J. J. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97, 3197-3204.
97. Wang, L., Zhang, Z., Brock, A. and Schultz, P. G. (2003) Addition of the keto functional group to the genetic code of Escherichia coli. Proc. Natl. Acad Sci. U.S.A. 100, 56-61.
98. Wong, W. M. (1999) Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer. Cancer Pract. 7, 48-50.
99. Yang, H. M. and Reisfeld, R. A. (1988) Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc. Natl. Acad Sci. U.S.A. 85, 1189-1193.
100. Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., Forero-Torres, A., Moskowitz, C. H., Connors, J. M., Engert, A., Larsen, E. K., Kennedy, D. A., Sievers, E. L. and Chen, R. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183-2189.
101. Young, T. S., Ahmad, I., Yin, J. A. and Schultz, P. G. (2010) An enhanced system for unnatural amino acid mutagenesis in E. coli. J. Mol. Biol. 395, 361-374.
102. Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., Lambert, J. M. and Chari, R. V. (2011) Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J. Med. Chem. 54, 3606-3623.